Clinical Trials Logo

Breast Inflammatory Carcinoma clinical trials

View clinical trials related to Breast Inflammatory Carcinoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03941756 Recruiting - Melanoma Clinical Trials

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

Start date: August 14, 2018
Phase: N/A
Study type: Interventional

This pilot trial studies whether a procedure called lymphovenous bypass would prevent lymphedema (arm swelling) in patients with inflammatory breast cancer or non-inflammatory breast cancer that has spread to nearby tissues or lymph nodes or melanoma. The lymphovenous bypass procedure creates a path for lymphatic fluid to flow away from the arms. It is usually done after a diagnosis of lymphedema. In this study, giving lymphovenous bypass before underarm lymph node surgery may help prevent lymphedema from forming.

NCT ID: NCT03598257 Recruiting - Clinical trials for Breast Inflammatory Carcinoma

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Start date: January 18, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.